Sugi Predict

Sugi Predict / Compounds / SCHEMBL29736864

SCHEMBL29736864

SCHEMBL29736864

CC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CN)C(C)C)[C@@H](C)O)C(C)C)C(C)C

nearest known ligand 0.72

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 6/20 0.72
▸ GHSR Q92847 4/20 0.68
▸ NPY2R P49146 3/20 0.68
▸ IL23R Q5VWK5 3/20 0.68
▸ GLP1R P43220 5/20 0.68
▸ CCKBR P32239 1/20 0.67
▸ ECE1 P42892 1/20 0.66
▸ MUS81 Q96NY9 1/20 0.66
▸ CALCA P06881 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29491080 0.97 NR3C1 (0.76) NR3C1GHSRNPY2RIL23RGLP1R
SCHEMBL29736869 0.95 NR3C1 (0.72) NR3C1GHSRNPY2RIL23RGLP1R
SCHEMBL30008855 0.92 NR3C1 (0.70) NR3C1GHSRNPY2RIL23RGLP1R
SCHEMBL31140800 0.91 GLP1R (0.70) NR3C1GLP1RCCKBRECE1MUS81
SCHEMBL30008333 0.90 PTH1R (0.66) NR3C1GLP1RCCKBRECE1MUS81
SCHEMBL29395456 0.89 GLP1R (0.78) NR3C1GHSRNPY2RIL23RGLP1R
SCHEMBL29357856 0.89 GLP1R (0.77) NR3C1GHSRNPY2RIL23RGLP1R
SCHEMBL29412274 0.88 GLP1R (0.73) NR3C1GLP1RCCKBRECE1MUS81
SCHEMBL30683162 0.88 GLP1R (0.81) NR3C1GHSRNPY2RGLP1RCCKBR
SCHEMBL29540128 0.88 GLP1R (0.79) NR3C1GHSRNPY2RGLP1RCCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-14 — — US claimed
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-07 — — US claimed
EP-4736856-A2 BICYCLIC AMINES AS CDK2 INHIBITORS Incyte Corporation (US) 2026-05-06 — — EP claimed
US-12600722-B2 Tetracyclic compounds as DGK inhibitors INCYTE CORPORATION (US) 2026-04-14 — — US claimed
US-12600723-B2 Tetracyclic compounds as DGK inhibitors INCYTE CORPORATION (US) 2026-04-14 — — US claimed
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 — — US claimed
US-20260098044-A1 TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 INCYTE CORP (US) 2026-04-09 — — US claimed
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS INCYTE CORP (US) 2026-03-12 — — US claimed
US-20260070914-A1 SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS INCYTE CORP (US) 2026-03-12 — — US claimed
EP-4041731-B1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORP (US) 2026-02-18 — — EP claimed
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-22 — — US claimed
WO-2023107705-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-15 — — WO claimed
US-20230183250-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-15 — — US claimed
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION 2023-06-15 — — US claimed
WO-2023102184-A1 BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-08 — — WO claimed
US-11447494-B2 Tricyclic amine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2022-09-20 — — US claimed
US-11440914-B2 Tricyclic amine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2022-09-13 — — US claimed
EP-4041731-A1 BICYCLIC AMINES AS CDK2 INHIBITORS Incyte Corporation (US) 2022-08-17 — — EP claimed
US-20220213108-A1 DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION 2022-07-07 — — US claimed
WO-2022140231-A1 DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION (US) 2022-06-30 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183250-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 NR3C1 1555/4885GHSR 4077/4885NPY2R 4214/4885
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS CDK4, CDK2, CCNC NR3C1 274/4885GHSR 1539/4885NPY2R 2650/4885
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 NR3C1 1555/4885GHSR 4077/4885NPY2R 4214/4885
US-20260070914-A1 SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS CCNA1, CCNO, CDK1 NR3C1 12/4885GHSR 206/4885NPY2R 978/4885
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS CDK12, CDK1, CDK2 NR3C1 3274/4885GHSR 4559/4885NPY2R 3507/4885
US-20220213108-A1 DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS JAK2, JAK1, VHL NR3C1 4012/4885GHSR 2202/4885NPY2R 3189/4885
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS CCNA1, CDK4, CCNO NR3C1 44/4885GHSR 323/4885NPY2R 2382/4885
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS WRN, POLR1A, REV1 NR3C1 7/4885GHSR 914/4885NPY2R 3410/4885
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS CDK4, CCNA1, CCNO NR3C1 72/4885GHSR 796/4885NPY2R 2494/4885
US-11447494-B2 Tricyclic amine compounds as CDK2 inhibitors CDK2, CDK1, CCNI NR3C1 2388/4885GHSR 4041/4885NPY2R 4223/4885
US-11440914-B2 Tricyclic amine compounds as CDK2 inhibitors CDK2, CDK1, CCNI NR3C1 2428/4885GHSR 4392/4885NPY2R 4516/4885
US-12600723-B2 Tetracyclic compounds as DGK inhibitors DGKB, DGKA, NR2C2 NR3C1 99/4885GHSR 845/4885NPY2R 1068/4885
US-20260098044-A1 TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 JAK1, TYK2, JAK2 NR3C1 25/4885GHSR 640/4885NPY2R 146/4885
US-12600722-B2 Tetracyclic compounds as DGK inhibitors DGKB, DGKA, DGKK NR3C1 193/4885GHSR 1285/4885NPY2R 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback